These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 68Ga DOTATATE PET/CT Versus 18F-FDG PET/CT for Detecting Intramedullary Hemangioblastoma in a Patient With Von Hippel-Lindau Disease. Banezhad F; Kiamanesh Z; Emami F; Sadeghi R Clin Nucl Med; 2019 Jun; 44(6):e385-e387. PubMed ID: 30985433 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033 [TBL] [Abstract][Full Text] [Related]
6. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206 [TBL] [Abstract][Full Text] [Related]
7. Al18F-NOTA-Octreotide PET/CT and 18F-FDG PET/CT for Detecting Cerebellar Hemangioblastoma in a Patient With Von Hippel-Lindau Disease. Hou G; Cheng X; Chi Y; Wang X; Zheng R Clin Nucl Med; 2024 Mar; 49(3):289-291. PubMed ID: 38306383 [TBL] [Abstract][Full Text] [Related]
8. Kidney Tumor in a von Hippel-Lindau (VHL) Patient With Intensely Increased Activity on 68Ga-DOTA-TATE PET/CT. Papadakis GZ; Millo C; Sadowski SM; Bagci U; Patronas NJ Clin Nucl Med; 2016 Dec; 41(12):970-971. PubMed ID: 27749408 [TBL] [Abstract][Full Text] [Related]
9. Different manifestations detected with 68Ga-DOTATOC PET/CT in patients with Von Hippel-Lindau disease: A case report. Meneret P; Girard A; Pagenault M; Riffaud L; Palard-Novello X Nuklearmedizin; 2020 Aug; 59(4):332-334. PubMed ID: 32193881 [No Abstract] [Full Text] [Related]
15. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350 [TBL] [Abstract][Full Text] [Related]
16. The utility of Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201 [TBL] [Abstract][Full Text] [Related]
18. Von Hippel-Lindau syndrome: demonstration of entire disease spectrum with (68)Ga-DOTANOC PET-CT. Sharma P; Dhull VS; Bal C; Malhotra A; Kumar R Korean J Radiol; 2014; 15(1):169-72. PubMed ID: 24497809 [TBL] [Abstract][Full Text] [Related]
19. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Velikyan I; Xu H; Nair M; Hall H Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375 [TBL] [Abstract][Full Text] [Related]
20. Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease. Oh JR; Kulkarni H; Carreras C; Schalch G; Min JJ; Baum RP Nucl Med Mol Imaging; 2012 Jun; 46(2):129-33. PubMed ID: 24900047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]